Translational Oncology最新文献_第4页

High expression of PAX8-AS1 correlates with poor prognosis and response to fluorouracil-based chemotherapy in stage II colon cancer PAX8-AS1 的高表达与 II 期结肠癌的不良预后和对氟尿嘧啶化疗的反应有关

IF 5 2区医学

Translational Oncology Pub Date : 2024-09-19 DOI: 10.1016/j.tranon.2024.102128

{"title":"High expression of PAX8-AS1 correlates with poor prognosis and response to fluorouracil-based chemotherapy in stage II colon cancer","authors":"","doi":"10.1016/j.tranon.2024.102128","DOIUrl":"10.1016/j.tranon.2024.102128","url":null,"abstract":"<div><p>Decisions regarding adjuvant therapy in patients with stage II colon cancer remains controversial and challenging. We aimed to determine novel biomarkers that help to predict relapse free survival (RFS) and identify a subset of patients with stage II colon cancer who could gain survival benefits from adjuvant chemotherapy. Public microarray datasets of stage II colon cancer samples were extracted from Gene Expression Omnibus database. Global gene expression changes were then analyzed between the paired early relapse and long-term survival group to identify the differentially expressed mRNAs and lncRNAs. Based on Lasso Cox regression modeling analysis, a total of 30 mRNAs and 2 lncRNAs were finally identified. With specific formula, stage II patients in training and validation sets were divided into low and risk groups with significantly different RFS. PAX8-AS1 is the novel lncRNA which showed the highest upregulation in early relapse group. Patients with high PAX8-AS1 expression level showed notably poorer RFS in both meta GEO cohort (<em>P</em> = 0.04, Figure 4B) and FUSCC cohort (<em>P</em> < 0.001, Figure 4C). Among the stage II patients with high PAX8-AS1 level, administration of fluorouracil-based adjuvant chemotherapy provided a substantial improvement in RFS (<em>P</em> = 0.002, Figure 3C). Further mechanistic study unveiled that PAX8-AS1 increases the response of CRC cells to chemotherapy <em>in vitro</em> and <em>in vivo</em> by maintaining the mRNA stability of PAX8. In conclusion, PAX8-AS1 as a novel and reliable biomarker for predicting prognosis and identification of patients with stage II disease who could gain survival benefit from fluorouracil-based adjuvant chemotherapy.</p></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1936523324002559/pdfft?md5=0ca261ac45f351c2b8ee844c16e75e7c&pid=1-s2.0-S1936523324002559-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142270986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Defining the mode of action of cisplatin combined with NUC-1031, a phosphoramidate modification of gemcitabine 确定顺铂与 NUC-1031（吉西他滨的磷酰胺修饰物）的联合作用模式

IF 5 2区医学

Translational Oncology Pub Date : 2024-09-18 DOI: 10.1016/j.tranon.2024.102114

{"title":"Defining the mode of action of cisplatin combined with NUC-1031, a phosphoramidate modification of gemcitabine","authors":"","doi":"10.1016/j.tranon.2024.102114","DOIUrl":"10.1016/j.tranon.2024.102114","url":null,"abstract":"<div><p>The combination of gemcitabine with platinum agents is a widely used chemotherapy regimen for a number of tumour types. Gemcitabine plus cisplatin remains the current therapeutic choice for biliary tract cancer. Gemcitabine is associated with multiple cellular drug resistance mechanisms and other limitations and has thereforelined in use. NUC-1031 (Acelarin) is a phosphorylated form of gemcitabine, protected by the addition of a phosphoramidate moiety, developed to circumvent the key limitations and generate high levels of the cytotoxic metabolite, dFdCTP. The rationale for combination of gemcitabine and cisplatin is determined by <em>in vitro</em> cytotoxicity. This, however, does not offer an explanation of how these drugs lead to cell death. In this study we investigate the mechanism of action for NUC-1031 combined with cisplatin as a rationale for treatment. NUC-1031 is metabolised to dFdCTP, detectable up to 72 h post-treatment and incorporated into DNA, to stall the cell cycle and cause DNA damage in biliary tract and ovarian cancer cell lines. In combination with cisplatin, DNA damage was increased and occurred earlier compared to monotherapy. The damage associated with NUC-1031 may be potentiated by a second mechanism, via binding the RRM1 subunit of ribonucleotide reductase and perturbing the nucleotide pools; however, this may be mitigated by increased RRM1 expression. The implication of this was investigated in case studies from a Phase I clinical trial to observe whether baseline RRM1 expression in tumour tissue at time of diagnosis correlates with patient survival.</p></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1936523324002419/pdfft?md5=b7a3a253dcc7bbdfc2c2866d9b317470&pid=1-s2.0-S1936523324002419-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142239775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A bright future for multidisciplinary approach to cancer care in the setting of limited resource 在资源有限的情况下，多学科癌症治疗方法前景光明

IF 5 2区医学

Translational Oncology Pub Date : 2024-09-17 DOI: 10.1016/j.tranon.2024.102124

引用次数: 0

SOX4 promotes vascular abnormality in glioblastoma and is a novel target to improve drug delivery SOX4 促进胶质母细胞瘤的血管异常，是改善给药的新靶点

IF 5 2区医学

Translational Oncology Pub Date : 2024-09-16 DOI: 10.1016/j.tranon.2024.102120

{"title":"SOX4 promotes vascular abnormality in glioblastoma and is a novel target to improve drug delivery","authors":"","doi":"10.1016/j.tranon.2024.102120","DOIUrl":"10.1016/j.tranon.2024.102120","url":null,"abstract":"<div><p>Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults with dismal prognosis. Vascular abnormality is a hallmark of GBM, and aggravates diseases progression by increasing hypoxia, inducing life-threaten edema and hindering drug delivery. Nonetheless, the intricate mechanism underlying vascular abnormality remains inadequately understood. Here, we revealed a key role of SOX4 on vascular abnormality in GBM. SOX4 expression was increased in endothelial cells (ECs) from human brain tumors compared with ECs from paired normal brain tissue. Knockdown of SOX4 in mouse brain ECs restrained cell migration and proliferation. Furthermore, <em>in vitro</em> suppression of SOX4 in brain ECs and <em>in vivo</em> conditional knockout of SOX4 in tumor ECs led to the downregulation of genes linked with vascular abnormality. Notably, specific depletion of SOX4 in ECs enhanced drug delivery and sensitive tumor to chemotherapeutic drugs in GBM. Taken together, these results demonstrated that SOX4 is a novel regulator for tumor angiogenesis and vascular abnormality in GBM. Our findings identify SOX4 as a potential vascular therapeutic target to improve drug delivery for GBM treatment.</p></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S193652332400247X/pdfft?md5=8f18ff30a8069e57f4498f743ca5c0b4&pid=1-s2.0-S193652332400247X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142239057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of concurrent chemoradiotherapy with paclitaxel-based or S-1 regimens in treating elderly patients with esophageal squamous cell carcinoma: A multi-center propensity-score matched study 基于紫杉醇或 S-1 方案的同期化放疗治疗老年食管鳞状细胞癌的疗效和安全性：一项多中心倾向分数匹配研究

IF 5 2区医学

Translational Oncology Pub Date : 2024-09-14 DOI: 10.1016/j.tranon.2024.102123

{"title":"Efficacy and safety of concurrent chemoradiotherapy with paclitaxel-based or S-1 regimens in treating elderly patients with esophageal squamous cell carcinoma: A multi-center propensity-score matched study","authors":"","doi":"10.1016/j.tranon.2024.102123","DOIUrl":"10.1016/j.tranon.2024.102123","url":null,"abstract":"<div><h3>Background</h3><p>Elderly patients with esophageal cancer can benefit from concurrent chemoradiotherapy (CCRT). However, the optimal concurrent chemotherapy regimen remains undetermined. We aimed to compare the efficacy and safety of CCRT with paclitaxel-based or S-1 regimens in treating elderly patients with esophageal squamous cell carcinoma (ESCC).</p></div><div><h3>Methods</h3><p>From January 2016 to November 2022, a total of 349 patients aged 70 and above with ESCC were included. The patient population was divided into two treatment groups: patients receiving paclitaxel-based CCRT were allocated to the TP group, and those receiving S-1 regimen CCRT were allocated to the S-1 group. Propensity score matching (PSM) was used to balance potential biases. Survival outcomes, overall response rate, and treatment-related toxicities were assessed.</p></div><div><h3>Results</h3><p>After PSM, there were 82 patients in each group. The median follow up of the surviving patients was 42.6 months (IQR 28.0–58.8 months). The 2-year overall survival (OS) rate (71.4% vs 65.4%; log-rank <em>P</em> = 0.010) and progression-free survival (PFS) rate (64.4% vs 58.0%; log-rank <em>P</em> = 0.048) were significantly higher in the TP group. Compared with the S-1 group, the TP group experienced a higher rate of grade 3 and above hematologic toxicities, such as leukopenia (47.6% vs 15.9%, <em>P</em> < 0.001) and neutropenia (35.4% vs 6.1%, <em>P</em> < 0.001). One patient in the TP group and two patients in the S-1 group had grade 5 toxic effects.</p></div><div><h3>Conclusions</h3><p>Our findings suggest that paclitaxel-based CCRT was well tolerated in elderly patients with ESCC and provided significant survival benefits over S-1 regimen.</p></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S193652332400250X/pdfft?md5=4201e3c09f1e50c74b2414b9c43fffc3&pid=1-s2.0-S193652332400250X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142232078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comprehensive review on recent advances in exosome isolation and characterization: Toward clinical applications 全面回顾外泌体分离和表征的最新进展：面向临床应用

IF 5 2区医学

Translational Oncology Pub Date : 2024-09-14 DOI: 10.1016/j.tranon.2024.102121

{"title":"A comprehensive review on recent advances in exosome isolation and characterization: Toward clinical applications","authors":"","doi":"10.1016/j.tranon.2024.102121","DOIUrl":"10.1016/j.tranon.2024.102121","url":null,"abstract":"<div><p>Exosomes are small, round vesicles in the 30 and 120 nm diameter range released by all living cell types. Exosomes play many essential functions in intercellular communication and tissue crosstalk in the human body. They can potentially be used as strong biomarkers and therapeutic agents for early diagnosis, therapy response, and prognosis of different diseases. The main requirements for exosomal large-scale clinical practice application are rapid, easy, high-yield, high purity, characterization, safety, low cost, and therapeutic efficacy. Depending on the sample types, environmental insults, and exosome quantity, exosomes can be isolated from various sources, including body fluids, solid tissues, and cell culture medium using different procedures. This study comprehensively analyzed the current research progress in exosome isolation and characterization strategies along with their advantages and disadvantages. The provided information will make it easier to select exosome separation methods based on the types of biological samples available, and it will facilitate the use of exosomes in translational and clinical research, particularly in cancer.</p><p><strong>Lay abstract</strong> Exosomes have recently received much attention due to their potential to function as biomarkers and novel therapeutic agents for early diagnosis, therapeutic response, and prognosis in various diseases. This review summarizes many approaches for isolating and characterizing exosomes, focusing on developing technologies, and provides an in-depth comparison and analysis of each method, including its principles, advantages, and limitations.</p></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1936523324002481/pdfft?md5=aa35800e03a6f6c513fc2cd66d9eeb2e&pid=1-s2.0-S1936523324002481-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142229077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterization of DNA damage repair pathway utilization in high-grade serous ovarian cancers yields rational therapeutic approaches 表征高级别浆液性卵巢癌中 DNA 损伤修复途径的利用情况，提供合理的治疗方法

IF 5 2区医学

Translational Oncology Pub Date : 2024-09-12 DOI: 10.1016/j.tranon.2024.102119

{"title":"Characterization of DNA damage repair pathway utilization in high-grade serous ovarian cancers yields rational therapeutic approaches","authors":"","doi":"10.1016/j.tranon.2024.102119","DOIUrl":"10.1016/j.tranon.2024.102119","url":null,"abstract":"<div><p>While poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have improved the prognosis of ovarian high-grade serous carcinoma (HGSC) tumors that are homologous recombination (HR) deficient (HRD), new therapeutic strategies are needed for tumors that are HR proficient (HRP) because they demonstrate greater resistance to current treatments and thus have poorer clinical outcomes. Additionally, clinical precautionary statements regarding potential risks associated with PARPi, such as myelodysplastic syndrome, highlight the need for combinatorial approaches that can lessen the dose and duration of PARPi treatment to reduce toxicities. Here, we evaluated DNA double-strand damage repair pathways in HRD and HRP ovarian cancer cell lines and found that in HRD cell lines, PARPi therapy reduced non-homologous end joining (NHEJ)-mediated repair, specifically due to decreased theta-mediated end-joining. The combination of PARPi with ATM serine/threonine kinase inhibitor (ATMi) suppressed both NHEJ and HR pathways in HRD and HRP cell lines, with synergistic increases in apoptosis and decreases in cell viability and colony formation. Interestingly, PARPi plus ATMi also decreased NF-κB p65 phosphorylation, which was not observed when PARPi was combined with inhibition of the ATR kinase (ATRi). These findings indicate that PARPi plus ATMi is a promising strategy for HGSC independent of underlying tumor HR status.</p></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1936523324002468/pdfft?md5=580e5f10a5b02eb990d448b737acd62a&pid=1-s2.0-S1936523324002468-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142167867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MG53 suppresses tumor growth via transcriptional inhibition of KIF11 in pancreatic cancer MG53 通过转录抑制 KIF11 抑制胰腺癌患者的肿瘤生长

IF 5 2区医学

Translational Oncology Pub Date : 2024-09-11 DOI: 10.1016/j.tranon.2024.102118

{"title":"MG53 suppresses tumor growth via transcriptional inhibition of KIF11 in pancreatic cancer","authors":"","doi":"10.1016/j.tranon.2024.102118","DOIUrl":"10.1016/j.tranon.2024.102118","url":null,"abstract":"<div><p>Pancreatic ductal adenocarcinoma (PDAC) poses a formidable challenge in oncology due to its limited treatment options and poor long-term survival rates. Our previous work identified MG53, a member of the tripartite motif family protein (TRIM72), as a key player in tissue repair with potential applications in regenerative medicine. Despite the focus on MG53’s cytosolic functions, its nuclear role in suppressing pancreatic cancer remains unknown. Through orthotopic and subcutaneous transplantation studies in mice, we observed enhanced tumor growth in MG53-deficient mice compared to wild-type counterparts. The overexpression of KIF11, a motor protein crucial for cell mitosis regulation, has been linked to the aggressive proliferation of pancreatic cancer cells. Confocal imaging confirmed MG53′s presence in the nucleus of human pancreatic cancer cells, while functional assays demonstrated its impact on KIF11 expression and subsequent cell proliferation. Mechanistically, we revealed MG53′s transcriptional control over KIF11, leading to cell cycle arrest. Our findings position MG53 as a promising tumor suppressor in PDAC, offering a novel avenue for therapeutic intervention by regulating KIF11 expression.</p></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1936523324002456/pdfft?md5=df16f9329ec363216f0fd7364e72d4ae&pid=1-s2.0-S1936523324002456-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142167152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EphA2 specific chimeric antigen receptor engineered T cells for the treatment of prostate cancer 用于治疗前列腺癌的 EphA2 特异性嵌合抗原受体工程 T 细胞

IF 5 2区医学

Translational Oncology Pub Date : 2024-09-09 DOI: 10.1016/j.tranon.2024.102111

{"title":"EphA2 specific chimeric antigen receptor engineered T cells for the treatment of prostate cancer","authors":"","doi":"10.1016/j.tranon.2024.102111","DOIUrl":"10.1016/j.tranon.2024.102111","url":null,"abstract":"<div><p>Erythropoietin-producing hepatocyte receptor A2 (EphA2) is an attractive target for immunotherapy due to its high expression in a variety of solid tumors including prostate cancer. Among various types of immunotherapeutics, chimeric antigen receptor T (CAR-T) cell therapy has made promising progress in hematological and solid tumors. Here, we detected the expression of EphA2 in prostate cancer cells and developed a second-generation CAR targeting EphA2 with CD28 as a co-stimulatory receptor to explore its tumor suppressive potential for prostate cancer in vitro <em>and</em> in vivo. EphA2 was highly expressed on the surface of PC3 and DU145 cells. EphA2 CART cells effectively inhibited prostate cancer growth in an antigen-dependent manner in vitro <em>and</em> in vivo. In addition, tumor cells could stimulate the proliferation of CAR-T cells and the release of cytokine IFN-γ in vitro. These findings shed light on EphA2 as a potential target for prostate cancer, promising EphA2 specific CAR-T cells for the treatment of prostate cancer.</p></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1936523324002389/pdfft?md5=80d564b9c6b4228dc69096825ed5d559&pid=1-s2.0-S1936523324002389-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142157885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Excavating regulated cell death signatures to predict prognosis, tumor microenvironment and therapeutic response in HR+/HER2- breast cancer 挖掘细胞死亡调控特征，预测HR+/HER2-乳腺癌的预后、肿瘤微环境和治疗反应。

IF 5 2区医学

Translational Oncology Pub Date : 2024-09-05 DOI: 10.1016/j.tranon.2024.102117

{"title":"Excavating regulated cell death signatures to predict prognosis, tumor microenvironment and therapeutic response in HR+/HER2- breast cancer","authors":"","doi":"10.1016/j.tranon.2024.102117","DOIUrl":"10.1016/j.tranon.2024.102117","url":null,"abstract":"<div><p>Regulated cell death (RCD) has been documented to have great potentials for discovering novel biomarkers and therapeutic targets in malignancies. But its role and clinical value in HR+/HER2- breast cancer, the most common subtype of breast cancer, are obscure. In this study, we comprehensively explored 12 types of RCD patterns and found extensive mutations and dysregulations of RCD genes in HR+/HER2- breast cancer. A prognostic RCD scoring system (CDScore) based on six critical genes (LEF1, SLC7A11, SFRP1, IGFBP6, CXCL2, STXBP1) was constructed, in which a high CDScore predicts poor prognosis. The expressions and prognostic value of LEF1 and SFRP1were also validated in our tissue microarrays. The nomogram established basing on CDScore, age and TNM stage performed satisfactory in predicting overall survival, with an area under the ROC curve of 0.89, 0.82 and 0.8 in predicting 1-year, 3-year and 5-year overall survival rates, respectively. Furthermore, CDScore was identified to be correlated with tumor microenvironments and immune checkpoints by excavation of bulk and single-cell sequencing data. Patients in CDScore high group might be resistant to standard chemotherapy and target therapy. Our results underlined the potential effects and importance of RCD in HR+/HER2- breast cancer and provided novel biomarkers and therapeutic targets for HR+/HER2- breast cancer patients.</p></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1936523324002444/pdfft?md5=021f6e226d0758f7b6b439faf1766bfc&pid=1-s2.0-S1936523324002444-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0